Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

NCT04346862 is registered in ClinicalTrials.gov with Hanmi Pharmaceutical Company Limited as lead sponsor.

NCT NCT04346862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04346862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
Lead sponsor
Hanmi Pharmaceutical Company Limited
Phase
Phase 4
Overall status
Unknown status
Start date
January 26, 2016
Completion date
June 30, 2020
Enrollment
636 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment